(Reuters) – The U.S. Food and Drug Administration on Wednesday authorized Novavax Inc’s COVID-19 vaccine as a booster for adults.
The booster authorization applies to people who are unable to get updated Omicron-tailored boosters, or those who would choose not to receive any other booster dose of a vaccine.
The regulator’s decision is in addition to the earlier clearance for the vaccine as a primary two-shot regimen for those 12 years and above.
The company, however, has been struggling with sales of the vaccine and in August had halved its full-year revenue forecast, saying it does not expect further sales of its COVID-19 shot in the United States this year.
(Reporting by Leroy Leo in Bengaluru; Editing by Anil D’Silva)
